Related Experiment Video
Updated: Jun 16, 2026
04:55
Testing of Nanoparticle Release from a Composite Containing Nanomaterial Using a Chamber System
Published on: November 22, 2016
Developing U.S. oversight strategies for nanobiotechnology: learning from past oversight experiences
Jordan Paradise1, Susan M Wolf, Jennifer Kuzma
1Seton Hall University School of Law, USA.
Summary
Emerging nanobiotechnology presents oversight challenges. Analyzing past efforts with genetically engineered organisms and other technologies offers lessons for effective nanotech regulation.
Area of Science:
- Nanotechnology
- Biotechnology
- Regulatory Science
Background:
- Nanotechnology and nanobiotechnology introduce complex regulatory challenges.
- Multiple US federal agencies (FDA, EPA, USDA, OSHA, NIH) are actively discussing oversight.
- Past oversight efforts for emerging technologies offer valuable lessons.
Purpose of the Study:
- To identify lessons from past oversight efforts for emerging technologies.
- To develop a new framework for evaluating oversight of nanobiotechnology.
Main Methods:
- Comparative analysis of five oversight case studies.
- Quantitative and qualitative analysis of oversight successes and failures.
- Focus on genetically engineered organisms (GEOs) in food, pharmaceuticals, medical devices, workplace chemicals, and gene therapy.
Main Results:
- Identified key successes and failures in past technology oversight.
- Developed a novel approach for evaluating oversight effectiveness.
- Provided insights applicable to nanobiotechnology regulation.
Conclusions:
- Effective oversight of nanobiotechnology requires learning from historical regulatory approaches.
- A systematic evaluation method is crucial for adapting oversight to new technologies.
- Interagency collaboration and adaptive strategies are essential for managing nanobiotechnology risks.
Related Concept Videos
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...